Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations-Reference-Cited by-同舟云学术

Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations

Published:2020-07-08 Issue:3 Volume:87 Page:905-915
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Sáez‐Belló Marina¹,Mangas‐Sanjuán Víctor²³^ORCID,Martínez‐Gómez Mª. Amparo¹,López‐Montenegro Soria Mª. Ángeles⁴,Climente‐Martí Mónica⁵,Merino‐Sanjuán Matilde²³

Affiliation:

1. Foundation for the Promotion of Health and Biomedical Research of Valencia, Department of Pharmacy Doctor Peset University Hospital Valencia Spain

2. Department of Pharmacy and Pharmaceutical Technology and Parasitology University of Valencia Valencia Spain

3. Interuniversity Research Institute for Molecular Recognition and Technological Development Polytechnic University of Valencia‐University of Valencia Valencia Spain

4. Department of Pharmacy Lluís Alcañís Hospital Xàtiva (Valencia) Spain

5. Department of Pharmacy Doctor Peset University Hospital Valencia Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14441

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

3. Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis